Oncology Letters is a prominent academic journal dedicated to disseminating high-quality research in the fields of oncology and cancer research. Published by SPANDIDOS PUBL LTD and based in Greece, this journal has established a significant presence since its inception in 2010 and continues to contribute to the scientific community with a focus on both clinical and experimental oncology. Notably, it holds a respectable Q3 ranking in the categories of Cancer Research and Oncology as of 2023, highlighting its relevance and contribution to these critical fields. With a Scopus rank of #139/404 in Medicine – Oncology and #117/230 in Biochemistry, Genetics, and Molecular Biology – Cancer Research, Oncology Letters serves as a valuable platform for researchers, professionals, and students alike to explore emerging findings and innovative treatment approaches. Though it operates within a traditional subscription model, this journal prides itself on fostering accessible and impactful discourse in oncology, making it an essential resource for those committed to advancing cancer research and improving patient care.

Cancers is a leading peer-reviewed journal published by MDPI, dedicated to advancing the field of oncology and cancer research. Established in 2009 and based in Switzerland, this Open Access journal provides a platform for the rapid dissemination of high-quality research findings, reviews, and clinical studies related to all aspects of cancer biology and treatment. With an impressive impact factor and recognized as Q1 in Oncology and Q2 in Cancer Research for 2023, Cancers strives to foster a collaborative environment among researchers, healthcare professionals, and students seeking to deepen their knowledge and understanding of cancer. The journal’s commitment to accessibility and its broad scope make it an invaluable resource for anyone passionate about combating cancer and improving patient outcomes. For more information and to access its diverse publications, visit the journal’s website.

Journal of Diabetes Investigation is a prestigious open-access journal published by WILEY, dedicated to advancing knowledge in the fields of Endocrinology, Diabetes, and Metabolism. With its ISSN 2040-1116 and E-ISSN 2040-1124, the journal provides a vital platform for researchers, healthcare professionals, and students to disseminate high-quality research, foster innovative ideas, and engage with cutting-edge developments in diabetes investigation. Since its inception in 2010, the journal has established a solid reputation, ranking in Q2 for Endocrinology and Diabetes and Metabolism, and Q1 for both Internal Medicine and Miscellaneous Medicine categories in 2023. Its Scopus rankings further underscore its impact, notably at the 76th percentile in Internal Medicine. The open access model, adopted in 2014, ensures that vital information is freely available, promoting global collaboration and knowledge sharing. The journal is not only a reflection of Australia's commitment to medical research but also a beacon for advancements that can ultimately enhance patient outcomes in diabetes care.

Pediatric Hematology and Oncology, published by Taylor & Francis Inc, serves as a vital platform dedicated to the fields of hematology, oncology, and pediatrics, providing a comprehensive avenue for the dissemination of scholarly research and clinical advancements. With an ISSN of 0888-0018 and an E-ISSN of 1521-0669, this journal has successfully converged its expertise over the years from 1984 to 2024. Ranked in the Q3 category for Hematology and Oncology, alongside a Q2 ranking in Pediatrics, Perinatology, and Child Health (2023), it engages a diverse readership comprising researchers, healthcare professionals, and students eager to explore groundbreaking studies in child health and treatment methodologies. While it currently does not offer Open Access options, the journal is widely cited and recognized, particularly in its specialized fields, fostering a rich environment for dialogue and innovation in the management of pediatric hematological and oncological disorders. The journal is based in the United Kingdom at 530 Walnut Street, Ste 850, Philadelphia, PA 19106, making it an essential resource for those pursuing excellence in pediatric medical research.

Rehabilitation Oncology, published by Lippincott Williams & Wilkins, is an essential academic journal dedicated to the interdisciplinary field of cancer rehabilitation. Since its inception in 2008, it has provided a platform for illuminating research, clinical practices, and innovative therapies aimed at improving the quality of life for cancer survivors. With an ISSN of 2168-3808 and an E-ISSN of 2381-2427, the journal covers a wide spectrum of topics, making significant contributions across various categories including Oncology, Rehabilitation, and Physical Therapy. Although currently not Open Access, the journal has garnered a notable 2023 Impact Factor status, placing it in the Q3 quadrant across multiple relevant disciplines as per the latest Scopus rankings. This reflects its growing influence in the rehabilitation community and offers vital insights for practitioners and researchers seeking to advance their understanding of patient care post-cancer treatment. With its focus on bridging the gap between research and real-world application, Rehabilitation Oncology serves as a vital resource for healthcare professionals committed to enhancing recovery outcomes in their patients.

The Lancet Oncology is a premier peer-reviewed journal published by Elsevier Science Inc., recognized as a leading authority in the field of oncology. With an ISSN of 1470-2045 and E-ISSN 1474-5488, this esteemed journal boasts an impressive 2023 impact factor placing it in the Q1 category of oncology—reflecting its role as a critical resource for cutting-edge research. The journal publishes high-quality articles covering novel scientific discoveries, clinical advancements, and public health issues related to cancer treatment and prevention. It is ranked #5 out of 404 in the Scopus Medicine _ Oncology category, demonstrating its influence and relevance in the field, with an outstanding rank in the 98th percentile. Operating from its base in the United Kingdom, The Lancet Oncology spans a comprehensive timeframe from 2000 to 2024, making it a vital repository of oncology literature. Although it does not primarily operate on an open-access model, its significant subscription base ensures that a wealth of knowledge is accessible to researchers, professionals, and students alike, fostering a profound understanding and advancement in oncology.

Breast Cancer Research and Treatment, published by Springer, stands as a pivotal journal within the domains of Cancer Research and Oncology, exemplified by its impressive Q2 and Q1 quartile rankings, respectively, in the 2023 category rankings. Since its inception in 1981, this journal has provided a vital platform for disseminating cutting-edge research focused on all aspects of breast cancer, ranging from molecular biology to treatment strategies. With an ISSN of 0167-6806 and E-ISSN of 1573-7217, it captures a broad audience of researchers, clinicians, and students dedicated to improving patient outcomes. The journal emphasizes high-quality, peer-reviewed studies that pave the way for advancements in therapy and direct novel insights into oncological practices. By maintaining a strong ranking in Scopus with percentile placements of 74th in Oncology and 61st in Cancer Research, Brest Cancer Research and Treatment continues to foster innovation and collaboration in the fight against breast cancer.

SUPPORTIVE CARE IN CANCER is a premier academic journal published by Springer, dedicated to advancing the understanding and management of supportive care for cancer patients. With a notable impact factor, the journal is recognized for its contribution to the fields of Oncology, Rehabilitation, and Nursing, achieving impressive rankings in Scopus, including Q1 for Oncology Nursing and Rehabilitation, and Q2 for general Oncology. Founded in 1993 and looking towards a promising future until 2024, it serves as a vital resource for researchers, professionals, and students engaged in these critical areas of healthcare. Although not an Open Access journal, its rigorous peer-reviewed articles provide valuable insights into innovative practices and evidence-based strategies that enhance patient quality of life during and after treatment. By bridging the gap between research and clinical practice, SUPPORTIVE CARE IN CANCER significantly influences patient outcomes and fosters interdisciplinary collaboration in patient support.

JCO Oncology Practice is a premier peer-reviewed journal published by Lippincott Williams & Wilkins, specializing in the intersection of oncology and health policy. Established as a vital resource since 2020, this journal serves as a platform for the dissemination of innovative research, policy analysis, and clinical practice advancements aimed at enhancing cancer care. With its impressive impact factor and recognition in the top quartile (Q1) across multiple categories including Health Policy and Oncology, JCO Oncology Practice ranks #3 in Oncology Nursing and consistently shares cutting-edge insights that drive improvements within the field. The journal is accessible to a broad audience through its open access options, ensuring that vital knowledge reaches practitioners, researchers, and students alike. By prioritizing the latest evidence-based practices and addressing contemporary challenges in cancer treatment, JCO Oncology Practice plays an essential role in shaping the future of oncology practice and policy in the United States and beyond.

Cancer Control is a prominent open-access journal published by SAGE Publications Inc, dedicated to advancing the field of oncology, hematology, and general medicine since its inception in 1995. With a focus on disseminating high-quality research, the journal contributes significantly to the knowledge base surrounding cancer prevention, treatment, and survivorship, making it a vital resource for researchers, healthcare professionals, and students alike. The journal currently holds a commendable position in the academic landscape, ranking in the Q2 category for both Hematology and Oncology, highlighting its impact and scholarly relevance. Available in an open-access format since 2018, Cancer Control ensures that critical findings are accessible to a broad audience, promoting collaboration and innovation in cancer-related research. Whether you're interested in the latest clinical trials, epidemiological studies, or public health initiatives, this journal serves as a key platform for sharing significant developments in cancer care and control.